The selection of growth arrest-specific 5 (GAS5), miR-29a-3p, and NOTCH2 as biomarkers for NAFLD can be attributed to their involvement in key biological processes such as inflammation, fibrosis, and cellular metabolism, all of which are central to the pathogenesis of NAFLD. Here, NOTCH2 is linked to metabolic dysfunction-associated steatotic liver disease.